Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Expensive Performer
13072.0000 -64.00 (-0.49%)
NSE Apr 22, 2025 15:53 PM
Volume: 32,585
 

13072.00
-0.49%
BP Wealth
commercial revenue (-24% YoY). As per our understanding, the company has not made any shipment Stock of its one key product (24% of CMS revenue ) in this calendar year. Reported EBITDA margin contracted by 369bps to 12.8% level (vs our estimate of 15.3%) impacted largely due to Increase in raw material prices and upfront costs for certain projects. However, management is confident of improving margin profile from the current level on the back of a strong order book in CMS business, better traction in GDS business, and cost optimization measures. NLL reported a PAT of INR 87mn...
Number of MF schemes increased from 16 to 23 in Mar 2025 qtr.
More from Neuland Laboratories Ltd.
Recommended